Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.

In patients with dactylitis, the mean change from baseline in dactylitis severity score was higher with apremilast versus placebo but did not reach statistical significance at week 24. 32 After 24 weeks of treatment, the placebo-controlled phase ended and the remaining placebo patients were re-randomized to either apremilast 20 mg BID or apremilast 30 mg BID. 32 The ACR20 response could be sustained among the patients who continued receiving treatment with apremilast through week 52.

also in 111,027 other papers